Icahn School of Medicine at Mount Sinai

 

Icahn School of Medicine at Mount Sinai
S

Leveraging Dysregulated Signaling Networks for Therapeutic Benefit in Myeloid Malignancies

By Icahn School of Medicine at Mount Sinai FEATURING Stephen Oh
By Icahn School of Medicine at Mount Sinai FEATURING Stephen Oh
9 views
July 2, 2024
0 Comments
Login to view comments. Click here to Login
Myeloid Malignancy Workshop
06:03
Icahn School of Medicine at Mount Sinai

Strategies to Overcome Immune Dysregulation in MPNs

Feat. C. Cimen Bozkus
26:23
Icahn School of Medicine at Mount Sinai

Boosting MHC:TCR Interactions in AML

Feat. I. Aifantis
20:26
Icahn School of Medicine at Mount Sinai

Therapeutic Targeting of RNA Splicing Factor Mutant Leukemias

Feat. O. Abdel-Wahab
03:33
Icahn School of Medicine at Mount Sinai

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associ…

Feat. K. Chin
36:18
Icahn School of Medicine at Mount Sinai

Stem Cell Pathways, Aging, and Cancer Evolution in MPN

Feat. C. Jamieson
28:30
Icahn School of Medicine at Mount Sinai

Leveraging Dysregulated Signaling Networks for Therapeutic Benefit i…

Feat. S. Oh
26:45
Icahn School of Medicine at Mount Sinai

Targeting Mutant Calreticulin in MPN

Feat. A. Mullally
18:59
Icahn School of Medicine at Mount Sinai

BMT for MDS: Updates and Tricky Case Discussion

Feat. A. DeZern
27:08
Icahn School of Medicine at Mount Sinai

Emerging Landscape of Treating Anemia in LR-MDS

Feat. R. Komrokji
29:54
Icahn School of Medicine at Mount Sinai

State-of-the-Art Management of Systemic Mastocytosis

Feat. D. DeAngelo
12:06
Icahn School of Medicine at Mount Sinai

MDS: Prospects for Individualized Therapy With Targeted Therapies Po…

Feat. L. Silverman
48:04
Icahn School of Medicine at Mount Sinai

Integrating Targeted Therapies in AML

Feat. H. Kantarjian
34:57
Icahn School of Medicine at Mount Sinai

BPDCN: Current and Future Directions

Feat. N. Pemmaraju